Tazocin Intervention Study | NCT00478855 | Trialant
CompletedInterventionalPhase 4Updated Dec 10, 2007
Tazocin Intervention Study
Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria
ClinicalTrials.gov ID
NCT00478855
Lead Sponsor
Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
500
Last Update Posted
Dec 10, 2007Estimated
Start Date
Sep 2006
Completion Date
Jun 2007Actual
Official Title
Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria
Brief Summary
To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection.
To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.
Bacterial Infections
Tazocin (Piperacillin/Tazobactem)
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All patients admitted or transferred to the ICU/pulmonary/Infection units
Patients of either sex, 18 years of age or older Patients who stay in units less than 48 hours will not be enrolled.
Primary Purpose
Prevention
Allocation
Non-Randomized
Interventional Model
Single Group Assignment
Masking
None (Open Label)
No central contacts
There are no central contacts for this study.
-
Beijing, 100730, China
Lead Sponsor
Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY